Myostatin, a member of the transforming growth factor beta (TGF‐β) superfamily that is
highly expressed in skeletal muscle, was first described in 1997. It has been known that loss …

The elusive promise of myostatin inhibition for muscular dys... : Current Opinion in Neurology
The elusive promise of myostatin inhibition for muscular dystrophy : Current Opinion in …

Genetic deletion of Myostatin, a member of the Transforming Growth Factor-beta family of
signalling molecules, resulted in excessive growth of skeletal muscle. It demonstrated the …

Myostatin, which was cloned in 1997, is a potent inhibitor of skeletal muscle growth and
member of the tumour growth factor-β family. Disruption of the myostatin gene in mice …

Myostatin is a negative regulator of muscle mass. Important advances in our understanding
of the complex biology of this factor have revealed the therapeutic potential of antagonizing …

In the past 20 years, myostatin, a negative regulator of muscle mass, has attracted attention
as a potential therapeutic target in muscular dystrophies and other conditions. Preclinical …

Myostatin, or GDF-8 (growth and differentiation factor-8), was first identified through
sequence identity with members of the BMP (bone morphogenetic protein)/TGF-β …

Myostatin inhibitors as therapies for muscle wasting associa... : Current Opinion in Supportive
and Palliative Care Myostatin inhibitors as therapies for muscle wasting associated with cancer …

Myostatin is a member of the transforming growth factor (TGF)-β superfamily. It is expressed
by animal and human skeletal muscle cells where it limits muscle growth and promotes …

In addition to gene correction therapy and cell transplantation techniques, multidisciplinary
approaches to drug discovery and development offer promising therapeutic strategies for …